Overview

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

Status:
Terminated

Trial end date:
2016-08-01

Target enrollment:

Participant gender:

Summary

This is a single-arm, non-masked, open-label, Phase II study of cetuximab + dasatinib in recurrent Squamous Cell Carcinoma of The Head and Neck (SCCHN) that has recurred after cetuximab-containing therapy (please see attached schema). The primary endpoint 12-week PFS.

Phase:

Phase 2

Details

Lead Sponsor:

Julie E. Bauman, MD, MPH
University of Pittsburgh

Collaborator:

Bristol-Myers Squibb

Treatments:

Cetuximab
Dasatinib